Clinical Scorecard: Epidemiological Insights on Human Metapneumovirus in Hospitalized Adults Aged 50 and Above with Acute Respiratory Infections
At a Glance
Category
Detail
Condition
Human metapneumovirus (hMPV) infection causing acute respiratory illness
Key Mechanisms
Respiratory virus spread via contact with contaminated surfaces or bodily fluids; affects upper and lower respiratory tract
Target Population
Middle-aged and older adults (≥50 years), especially those who are frail or have comorbidities
Care Setting
Hospitalized patients with acute respiratory infections
Key Highlights
Frailty is significantly associated with severe hMPV infection, including increased oxygen therapy need and longer hospital stays.
Comorbidities such as cardiac illness, congestive heart failure, and chronic obstructive pulmonary disease increase odds of severe disease.
No specific antiviral treatments or licensed vaccines currently exist; management is supportive care and prevention.
Guideline-Based Recommendations
Diagnosis
Laboratory confirmation of hMPV infection via multiplex RT-PCR from nasopharyngeal swabs in hospitalized patients with acute respiratory illness.
Management
Supportive care including oxygen therapy, antipyretics, and intravenous fluids as needed.
Recognition and assessment of frailty using standardized tools to guide clinical management.
Monitoring & Follow-up
Monitor for severe disease indicators: pneumonia, oxygen requirement, ICU admission, mechanical ventilation, and mortality within 30 days.
Risks
Increased risk of severe disease in patients with frailty, cardiac illness, congestive heart failure, and chronic obstructive pulmonary disease.
Patient & Prescribing Data
Hospitalized adults aged 50 years and older with laboratory-confirmed hMPV infection
No specific antiviral treatment available; supportive care remains the mainstay. Frailty assessment is important for risk stratification and may inform future vaccination strategies.
Clinical Best Practices
Assess frailty status in all hospitalized older adults with hMPV to identify those at higher risk of severe outcomes.
Provide supportive care tailored to severity, including oxygen therapy and hydration.
Consider comorbid conditions such as cardiac disease and COPD when evaluating prognosis and management plans.
Prepare for longer hospital stays in frail patients and monitor closely for complications.
Incorporate frailty as a criterion in future vaccination and prevention strategies once hMPV vaccines become available.
by Henrique Pott, Jason J LeBlanc, May ElSherif, Todd F Hatchette, Melissa K Andrew, Shelly A McNeil, on behalf of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network
